tiprankstipranks
Trending News
More News >

BioNTech price target raised to $155 from $151 at Truist

Truist raised the firm’s price target on BioNTech to $155 from $151 and keeps a Buy rating on the shares. The firm notes BioNTech (BNTX) and Bristol Myers (BMY) have entered into a deal to co-develop and co-commercialize BNT327. Truist thinks this is a good deal for BioNTech as it shares/derisks the considerable R&D expense, taps into the expertise of a leading IO drug developer with the footprint and infrastructure needed to maximize BNT327, and gives BioNTech $3.5B in upfront and near-term cash, plus $7.6B in potential milestones. All things considered, the firm thinks 50% profit share is fair, and positions BioNTech as an equal in this deal.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue